Home » Stocks » REPL

Replimune Group, Inc. (REPL)

Stock Price: $35.05 USD 0.36 (1.04%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $34.00 -1.05 (-3.00%) May 14, 6:10 PM
Market Cap 1.63B
Revenue (ttm) n/a
Net Income (ttm) -75.16M
Shares Out 49.38M
EPS (ttm) -1.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $35.05
Previous Close $34.69
Change ($) 0.36
Change (%) 1.04%
Day's Open 35.21
Day's Range 34.05 - 36.35
Day's Volume 281,514
52-Week Range 17.50 - 54.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WOBURN, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today annou...

6 days ago - GlobeNewsWire

WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today annou...

1 week ago - GlobeNewsWire

Event to begin at 8:00 AM ET Event to begin at 8:00 AM ET

2 weeks ago - GlobeNewsWire

Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.

Other stocks mentioned: AMGN, BMY, REGN, RHHBY, SNY
3 weeks ago - GuruFocus

Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2

1 month ago - GlobeNewsWire

Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fun...

Other stocks mentioned: FGEN, IMTX
1 month ago - Benzinga

WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...

2 months ago - GlobeNewsWire

WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...

2 months ago - GlobeNewsWire

WOBURN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today anno...

2 months ago - GlobeNewsWire

RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across al...

3 months ago - GlobeNewsWire

Replimune is developing a handful of oncolytic immunotherapies therapies targeting cancers. The company has nearly half a billion dollars in cash.

5 months ago - Seeking Alpha

One has a better chance to keep climbing than the other does.

Other stocks mentioned: SURF
6 months ago - The Motley Fool

RP1 : Updated deep and durable response data with Opdivo ® in CSCC and anti- PD1 failed melanoma continue to support ongoing registration-directed development

6 months ago - GlobeNewsWire

Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.

Other stocks mentioned: SRRK
6 months ago - The Motley Fool

BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced t...

6 months ago - GlobeNewsWire

BOSTON, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a...

6 months ago - GlobeNewsWire

WOBURN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced ...

6 months ago - GlobeNewsWire

WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today anno...

6 months ago - GlobeNewsWire

The company plans to present encouraging early-stage clinical data at a major conference next month.

7 months ago - The Motley Fool

I nitial safety and efficacy data from the single agent RP2 portion of the Phase 1 clinical trial of RP2 alone & in combination with Opdivo® ( nivolumab ) in patients with solid tumors

7 months ago - GlobeNewsWire

WOBURN, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today annou...

7 months ago - GlobeNewsWire

Clinical proof of principle established with RP1 in combination with Opdivo® for the treatment of immune-responsive tumors supporting registration directed development in CSCC and anti-PD1 refractory me...

9 months ago - GlobeNewsWire

WOBURN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL) a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...

9 months ago - GlobeNewsWire

WOBURN, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today an...

9 months ago - GlobeNewsWire

WOBURN, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...

10 months ago - GlobeNewsWire

Replimune (REPL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

WOBURN, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing a series of oncolytic immuno-gene therapies derived from its Immulytic™ platfo...

11 months ago - GlobeNewsWire

WOBURN, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today an...

1 year ago - GlobeNewsWire

RP1: Registration-directed randomized controlled Phase 2 clinical trial of RP1 in combination with cemiplimab-rwlc (Libtayo®) in cutaneous squamous cell carcinoma (CSCC) underway

1 year ago - GlobeNewsWire

WOBURN, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...

1 year ago - GlobeNewsWire

WOBURN, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...

1 year ago - GlobeNewsWire

Did you know that the GuruFocus All-in-One Screener can be used to find insider trades from a specific period of time or a certain range of value?

Other stocks mentioned: ET, KDMN
1 year ago - GuruFocus

BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced...

1 year ago - GlobeNewsWire

BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced...

1 year ago - GlobeNewsWire

Data demonstrate RP1 alone and combined with Opdivo® is well tolerated with anti-tumor efficacy in target tumor types

1 year ago - GlobeNewsWire

Replimune’s second product candidate to enter the clinic is an Immulytic™ that expresses an anti-CTLA-4 antibody-like protein Replimune’s second product candidate to enter the clinic is an Immulytic™ th...

1 year ago - GlobeNewsWire

Abstract highlights initial data from Phase 1 part of Phase 1/2 clinical trial of RP1 alone and in combination with Opdivo® (nivolumab) Abstract highlights initial data from Phase 1 part of Phase 1/2 cl...

1 year ago - GlobeNewsWire

Shares have lost 4% of their value since my April article.

1 year ago - Seeking Alpha

Share price performance is relatively flat since July 2018 IPO.

2 years ago - Seeking Alpha

Replimune Group Inc (NASDAQ: REPL)'s lead asset is expected to quickly pass through development and clear the FDA hurdle, according to Wedbush. 

2 years ago - Benzinga

About REPL

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, wh... [Read more...]

Industry
Biotechnology
IPO Date
Jul 20, 2018
CEO
philip Astley-Sparke
Employees
122
Stock Exchange
NASDAQ
Ticker Symbol
REPL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for REPL stock is "Buy." The 12-month stock price forecast is 56.30, which is an increase of 60.63% from the latest price.

Price Target
$56.30
(60.63% upside)
Analyst Consensus: Buy